ZWZhichong Wu

Zhichong Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhichong Wu has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Role of the early stage stroma-immune interactions in the tumor microenvironment of pancreatic adenocarcinoma

    by Zhichong Wu

    Rôle des interactions stromal-immunes à un stade précoce dans le microenvironnement tumoral de l'adénocarcinome pancréatique: Pendant de nombreuses années, lors des pratiques cliniques, l'adénocarcinome canalaire pancréatique (PDAC) a été considéré comme ‘le seigneur du cancer’ par les chirurgiens et les oncologues. Une quantité excessive de tissu desmoplastique jusqu'à 80-90% est une caractéristique du PDAC par rapport à d'autres tumeurs malignes. L'interaction entre les cellules stromales et les cellules cancéreuses dans le microenvironnement tumoral (TME) contribue à la progression tumorale et à la résistance thérapeutique. Les mécanismes dont le stroma module la progression tumorale dans le PDAC ne sont pas encore entièrement compris. Notre étude sur les interactions stroma-système immunitaire au stade précoce du PDAC sont essentielles pour comprendre les mécanismes immunosuppresseurs dans ce cancer. Dans ma thèse de doctorat, à travers l'identification d'une protéine de la matrice extracellulaire stromale βig-h3 et d'une sous-population de cellules souches localisées dans le stroma de TME, appelées cellules souches péricytaires (PeSC), nous avons démontré que les composants du stroma sont fortement impliqués au stade d'initiation du PDAC, favorisant la croissance tumorale, créant un TME immunosuppresseur et modulant la quantité et la qualité des cellules immunitaires recrutées ou résidentes. Nous avons montré par des expériences in vivo l'implication de ce compartiment stromal dans la résistance à l'immunothérapie anti-PD-1. Par conséquent, l'élimination de la protéine βig-h3 par une approche anticorps ou le ciblage des PeSC ont montré des potentiels pour restaurer l'immunité antitumorale, le remodelage du microenvironnement immunosuppresseur et libérer l'efficacité des immunothérapies existantes pour le PDAC.

  • Open Access

    Stiffness-induced cancer-associated fibroblasts are responsible for immunosuppression in a platelet-derived growth factor ligand-dependent manner

    by Pia Gamradt, Kevin Thierry, Melissa Masmoudi, Zhichong Wu, Hector Hernandez-Vargas, Sophie Bachy, Tiffanie Antonio, Berkan Savas, Zainab Hussain, Richard Tomasini, et al.

    Pancreatic ductal adenocarcinoma (PDAC) is associated with a vast stromal reaction that arises mainly from cancer-associated fibroblasts (CAFs) and promotes both immune escape and tumor growth. Here, we used a mouse model with deletion of the activin A receptor ALK4 in the context of the KrasG12D mutation, which strongly drives collagen deposition that leads to tissue stiffness. By ligand–receptor analysis of single-cell RNA-sequencing data, we identified that, in stiff conditions, neoplastic ductal cells instructed CAFs through sustained platelet-derived growth factor (PDGF) signaling. Tumor-associated tissue rigidity resulted in the emergence of stiffness-induced CAFs (siCAFs) in vitro and in vivo. Similar results were confirmed in human data. siCAFs were able to strongly inhibit CD8+ T-cell responses in vitro and in vivo, promoting local immunosuppression. More importantly, targeting PDGF signaling led to diminished siCAF and reduced tumor growth. Our data show for the first time that early paracrine signaling leads to profound changes in tissue mechanics, impacting immune responses and tumor progression. Our study highlights that PDGF ligand neutralization can normalize the tissue architecture independent of the genetic background, indicating that finely tuned stromal therapy may open new therapeutic avenues in pancreatic cancer.


  • Open Access

    Data from Oncogene-Induced Senescence Limits the Progression of Pancreatic Neoplasia through Production of Activin A

    by Yajie Zhao, Zhichong Wu, Marie Chanal, Fabienne Guillaumond, Delphine Goehrig, Sophie Bachy, Moitza Principe, Audrey Ziverec, Jean-Michel Flaman, Guillaume Collin, et al.

    Pancreatic ductal adenocarcinoma (PDAC) is a deadly and aggressive cancer. Understanding mechanisms that drive preneoplastic pancreatic lesions is necessary to improve early diagnostic and therapeutic strategies. Mutations and inactivation of activin-like kinase (ALK4) have been demonstrated to favor PDAC onset. Surprisingly, little is known regarding the ligands that drive ALK4 signaling in pancreatic cancer or how this signaling pathway limits the initiation of neoplastic lesions. In this study, data mining and histologic analyses performed on human and mouse tumor tissues revealed that activin A is the major ALK4 ligand that drives PDAC initiation. Activin A, which is absent in normal acinar cells, was strongly induced during acinar-to-ductal metaplasia (ADM), which was promoted by pancreatitis or the activation of KrasG12D in mice. Activin A expression during ADM was associated with the cellular senescence program that is induced in precursor lesions. Blocking activin A signaling through the use of a soluble form of activin receptor IIB (sActRIIB-Fc) and ALK4 knockout in mice expressing KrasG12D resulted in reduced senescence associated with decreased expression of p21, reduced phosphorylation of H2A histone family member X (H2AX), and increased proliferation. Thus, this study indicates that activin A acts as a protective senescence-associated secretory phenotype factor produced by Kras-induced senescent cells during ADM, which limits the expansion and proliferation of pancreatic neoplastic lesions.Significance:This study identifies activin A to be a beneficial, senescence-secreted factor induced in pancreatic preneoplastic lesions, which limits their proliferation and ultimately slows progression into pancreatic cancers.

  • Open Access

    Pericyte stem cells induce Ly6G+ cell accumulation and immunotherapy resistance in pancreatic cancer

    by Zhichong Wu, Kevin Thierry, Sophie Bachy, Xinyi Zhang, Pia Gamradt, Hector Hernandez‐Vargas, Ivan Mikaelian, Laurie Tonon, Roxanne Pommier, Yajie Zhao, et al.

    We report the identification of a cell population that shares pericyte, stromal and stemness features, does not harbor the Kras G12D mutation and drives tumoral growth in vitro and in vivo. We term these cells pericyte stem cells (PeSCs) and define them as CD45−EPCAM−CD29+CD106+CD24+CD44+ cells. We perform studies with p48‐Cre;Kras G12D (KC), pdx1‐Cre;Kras G12D ;Ink4a/Arf fl/fl (KIC) and pdx1‐Cre;Kras G12D ;p53 R172H (KPC) and tumor tissues from PDAC and chronic pancreatitis patients. We also perform single‐cell RNAseq analysis and reveal a unique signature of PeSC. Under steady‐state conditions, PeSCs are barely detectable in the pancreas but present in the neoplastic microenvironment both in humans and mice. The coinjection of PeSCs and tumor epithelial cells leads to increased tumor growth, differentiation of Ly6G+ myeloid‐derived suppressor cells, and a decreased amount of F4/80+ macrophages and CD11c+ dendritic cells. This population induces resistance to anti‐PD‐1 immunotherapy when coinjected with epithelial tumor cells. Our data reveal the existence of a cell population that instructs immunosuppressive myeloid cell responses to bypass PD‐1 targeting and thus suggest potential new approaches for overcoming resistance to immunotherapy in clinical settings.


  • Open Access

    Dipeptidyl peptidase-4 is associated with myogenesis in patients with adolescent idiopathic scoliosis possibly via mediation of insulin sensitivity

    by Zhicheng Dai, Zhenhua Feng, Zhichong Wu, Yuwen Wang, Zezhang Zhu, Yong Qiu, Leilei Xu